Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to
pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of
treatment in patients with type 2 diabetes.